[go: up one dir, main page]

FI2442650T4 - Kielen alle annettava apomorfiini - Google Patents

Kielen alle annettava apomorfiini

Info

Publication number
FI2442650T4
FI2442650T4 FIEP10786915.8T FI10786915T FI2442650T4 FI 2442650 T4 FI2442650 T4 FI 2442650T4 FI 10786915 T FI10786915 T FI 10786915T FI 2442650 T4 FI2442650 T4 FI 2442650T4
Authority
FI
Finland
Prior art keywords
pharmaceutical composition
composition according
apomorphine
unit dosage
dosage form
Prior art date
Application number
FIEP10786915.8T
Other languages
English (en)
Swedish (sv)
Inventor
Anthony Giovinazzo
David Hedden
Somer Marc De
Nathan Bryson
Original Assignee
Sunovion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43309244&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI2442650(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sunovion Pharmaceuticals Inc filed Critical Sunovion Pharmaceuticals Inc
Application granted granted Critical
Publication of FI2442650T4 publication Critical patent/FI2442650T4/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (13)

Patenttivaatimukset
1. Lääkekoostumus yksikköannosmuodossa, joka on muodostettu kielen alle antamista varten, joka mainittu yksikköannosmuoto on kalvo tai liuska, jossa on ensimmäinen kerros ja toinen kerros, jolloin ensimmäinen kerros on hapan ja käsittää apomorfiinihiukkasia, jotka käsittävät apomorfiinin happoadditiosuolaa, ja toinen kerros käsittää pH:ta neutraloivaa ainetta.
2. Patenttivaatimuksen 1 mukainen lääkekoostumus, jossa mainittu kalvomuoto käsittää polysakkaridia.
3. Jommankumman patenttivaatimuksen 1-2 mukainen lääkekoostumus, jossa mainittu — yksikköannosmuoto käsittää limakalvoon tarttuvaa polymeeriä.
4. Patenttivaatimuksen 3 mukainen lääkekoostumus, jossa mainittu limakalvoon tarttuva polymeeri — käsittää —karboksimetyyliselluloosaa, — selluloosa-asetaattia, = etyyliselluloosaa, hydroksietyyliselluloosaa tai hydroksipropyylimetyyliselluloosaa.
5. Jonkin edellisen patenttivaatimuksen mukainen lääkekoostumus, joka käsittää lisäksi — antioksidanttia.
6. Jonkin edellisen patenttivaatimuksen mukainen lääkekoostumus, joka käsittää lisäksi läpäisyä tehostavaa ainetta.
7. Patenttivaatimuksen 6 mukainen lääkekoostumus, jossa mainittu läpäisyä tehostava aine on glyserolimonostearaatti.
— 8. Jonkin edellisen patenttivaatimuksen mukainen lääkekoostumus, jossa mainittu pH:ta neutraloiva aine on orgaaninen emäs.
9. Jonkin edellisen patenttivaatimuksen mukainen lääkekoostumus, jossa mainittu ensimmäinen osa käsittää apomorfiinihiukkasia, joiden tehollinen hiukkaskoko on 1-10 um.
10. Jonkin edellisen patenttivaatimuksen mukainen lääkekoostumus, jossa mainittu apomorfiinin — happoadditiosuola on apomorfiinihydrokloridi.
11. Jonkin — patenttivaatimuksen 1-10 —mukainen — lääkekoostumus, — jossa — mainittu yksikköannosmuoto käsittää 2-40 mg apomorfiinia tai sen happoadditiosuolaa.
12. Jonkin patenttivaatimuksen 1-11 mukainen lääkekoostumus käytettäväksi Parkinsonin taudin, dyskinesian, akinesian hoidossa Parkinsonin tautia sairastavalla nisäkkäällä.
13.Jonkin patenttivaatimuksen 1-12 mukainen lääkekoostumus käytettäväksi seksuaalisen toimintahäiriön hoidossa.
FIEP10786915.8T 2009-06-12 2010-06-11 Kielen alle annettava apomorfiini FI2442650T4 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18644509P 2009-06-12 2009-06-12
PCT/US2010/038336 WO2010144817A1 (en) 2009-06-12 2010-06-11 Sublingual apomorphine

Publications (1)

Publication Number Publication Date
FI2442650T4 true FI2442650T4 (fi) 2025-08-06

Family

ID=43309244

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP10786915.8T FI2442650T4 (fi) 2009-06-12 2010-06-11 Kielen alle annettava apomorfiini

Country Status (20)

Country Link
US (10) US9044475B2 (fi)
EP (3) EP2442650B2 (fi)
JP (6) JP5760295B2 (fi)
KR (5) KR20170027711A (fi)
CN (1) CN102480958B (fi)
AU (4) AU2010259971C1 (fi)
BR (1) BR112012000204B8 (fi)
CA (1) CA2765291C (fi)
DK (2) DK2442650T4 (fi)
EA (1) EA025054B1 (fi)
ES (2) ES2699077T3 (fi)
FI (1) FI2442650T4 (fi)
HU (1) HUE028121T2 (fi)
IL (2) IL216923A (fi)
MX (1) MX2011013260A (fi)
NZ (1) NZ597237A (fi)
PL (2) PL2952191T3 (fi)
PT (2) PT2952191T (fi)
WO (1) WO2010144817A1 (fi)
ZA (1) ZA201109208B (fi)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110033542A1 (en) * 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
WO2010086989A1 (ja) 2009-01-29 2010-08-05 日東電工株式会社 口腔内フィルム状基剤及び製剤
US9044475B2 (en) 2009-06-12 2015-06-02 Cynapsus Therapeutics, Inc. Sublingual apomorphine
JP5751868B2 (ja) * 2010-03-30 2015-07-22 日東電工株式会社 フィルム状製剤及びその製造方法
ES2791715T3 (es) * 2010-12-16 2020-11-05 Sunovion Pharmaceuticals Inc Películas sublinguales
KR20160120785A (ko) 2011-08-17 2016-10-18 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 경구 전달 시스템을 통해 생리학적 및 치료학적 수준의 일산화질소를 생산하는 방법
JP5841433B2 (ja) 2012-01-11 2016-01-13 日東電工株式会社 口腔内フィルム状基剤及び製剤
US20140073678A1 (en) * 2012-09-12 2014-03-13 Monosol Rx, Llc Anti-pain and anti-nausea and/or vomiting combinatorial compositions
GB201217419D0 (en) 2012-09-28 2012-11-14 Innotesto Bvba Improvements in or relating to oromucosal apomorphine compositions
KR20160108828A (ko) 2013-11-11 2016-09-20 임팩스 라보라토리즈, 인코포레이티드 신속하게 붕괴되는 제형 및 사용 방법
EP2979688A1 (en) * 2014-08-01 2016-02-03 Britannia Pharmaceuticals Limited Composition containing Apomorphine and a Divalent Metal Cation
WO2016172095A1 (en) 2015-04-21 2016-10-27 Cynapsus Therapeutics, Inc. Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
CA3015172A1 (en) 2016-02-18 2017-08-24 Privo Technologies, Inc. Two-stage microparticle-based therapeutic delivery system and method
BR112019012683B1 (pt) 2016-12-22 2023-11-07 Nissan North America, Inc. Sistema remoto para um veículo autônomo
WO2018151849A1 (en) 2017-02-17 2018-08-23 Privo Technologies, Inc. Particle-based multi-layer therapeutic delivery device and method
DE102017108611A1 (de) 2017-04-21 2018-10-25 Technische Universität Clausthal Energie-effizientes lösungsmittelfreies Verfahren zur Herstellung von Aminosäure-Metallchelaten
US10478403B1 (en) 2017-05-03 2019-11-19 Privo Technologies, Inc. Intraoperative topically-applied non-implantable rapid release patch
JP6958860B2 (ja) * 2017-11-07 2021-11-02 学校法人自治医科大学 ミトコンドリアの機能障害の改善剤、及びミトコンドリアの機能障害に起因する疾患又は症状の予防又は治療薬、並びにそれらの用途
CA3091443A1 (en) * 2018-02-22 2019-08-29 Avior, Inc. Transmucosal film composition and methods of making and using the same
WO2019175290A1 (en) 2018-03-13 2019-09-19 Beckley Canopy Therapeutics Limited Cannabis or cannabis derived compositions for promoting cessation of chemical dependence
EP3813789A1 (en) 2018-06-28 2021-05-05 Arx, LLC Dispensing method for producing dissolvable unit dose film constructs
EP3989909A1 (en) 2019-06-27 2022-05-04 Sunovion Pharmaceuticals Inc. Child-resistant dispensers for thin strip medications
US11179331B1 (en) 2020-04-21 2021-11-23 Cure Pharmaceutcai Holding Corp Oral soluble film containing sildenafil citrate
US20230277449A1 (en) * 2020-07-15 2023-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Oral cavity polymeric delivery systems
CN115671106B (zh) * 2021-07-21 2024-03-19 广州新济药业科技有限公司 吗啡的应用

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1234123A (en) * 1915-08-25 1917-07-24 Charles L Bond Weighing device.
US3972995A (en) 1975-04-14 1976-08-03 American Home Products Corporation Dosage form
DE3013839A1 (de) 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
US4687773A (en) 1983-03-28 1987-08-18 Mclean Hospital (+)-N-N-propylnorapomorphine and selective limbic activity
US4746508A (en) 1983-06-06 1988-05-24 Beth Israel Hospital Assn. Drug administration
US4614545A (en) * 1985-08-15 1986-09-30 The Dow Chemical Company Hydroxypropyl methyl cellulose thickening agents for organic liquids
US5047244A (en) 1988-06-03 1991-09-10 Watson Laboratories, Inc. Mucoadhesive carrier for delivery of therapeutical agent
DE4018247A1 (de) * 1990-06-07 1991-12-12 Lohmann Therapie Syst Lts Herstellungsverfahren fuer schnellzerfallende folienfoermige darreichungsformen
US5292520A (en) 1990-09-13 1994-03-08 Akzo N.V. Stabilized solid pharmaceutical composition containing acid addition salts of a basic drug and an alkaline stabilizer
AU642066B2 (en) 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
WO1993025168A1 (en) * 1992-06-11 1993-12-23 Theratech, Inc. The use of glycerin in moderating transdermal drug delivery
AU660852B2 (en) 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5700478A (en) * 1993-08-19 1997-12-23 Cygnus, Inc. Water-soluble pressure-sensitive mucoadhesive and devices provided therewith for emplacement in a mucosa-lined body cavity
US6121276A (en) * 1994-04-22 2000-09-19 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
US6395744B1 (en) * 1994-04-22 2002-05-28 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
DE10199068I2 (de) * 1994-04-22 2004-05-06 Pentech Pharmaceuticals Inc Sublinguale Dosierungsformen enthaltend apomorphinzur Verwendung bei der Behandlung von erektiler D ysfunktion.
US6566368B2 (en) * 1994-04-22 2003-05-20 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage form for ameliorating male erectile dysfunction
US5718388A (en) 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
JPH0834731A (ja) * 1994-07-26 1996-02-06 T T S Gijutsu Kenkyusho:Kk グラニセトロン含有経皮吸収型製剤
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5560932A (en) * 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5543133A (en) 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5523090A (en) 1995-02-24 1996-06-04 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Skin treatment composition
US5888534A (en) * 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB9517062D0 (en) 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
US5800832A (en) 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
US20010006677A1 (en) 1996-10-29 2001-07-05 Mcginity James W. Effervescence polymeric film drug delivery system
DE19646392A1 (de) 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
DE19652268C2 (de) 1996-12-16 2000-06-29 Lohmann Therapie Syst Lts Arzneizubereitung für die Freisetzung von Apomorphin in der Mundhöhle
US6667056B2 (en) * 1997-07-23 2003-12-23 Chiesi Farmaceutici S.P.A. Pharmaceutical compositions containing an effervescent acid-base couple
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
US6974590B2 (en) * 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US7087240B1 (en) * 1998-06-25 2006-08-08 Lavipharm Laboratories Inc. Device and method for the treatment of erectile dysfunction
US5994363A (en) * 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
GB9826192D0 (en) 1998-12-01 1999-01-20 Controlled Theraputics Scotlan Oral transmucosal delivery
US6486207B2 (en) 1998-12-10 2002-11-26 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6552024B1 (en) * 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
US6087362A (en) * 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition
US6375963B1 (en) 1999-06-16 2002-04-23 Michael A. Repka Bioadhesive hot-melt extruded film for topical and mucosal adhesion applications and drug delivery and process for preparation thereof
CA2349406C (en) * 1999-09-03 2011-01-11 Amgen Inc. Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
DE19954245A1 (de) * 1999-11-11 2001-07-19 Lohmann Therapie Syst Lts Mehrschichtige filmförmige Zubereitung aus hydrophilen Polymeren zur schnellen Freisetzung von Wirkstoffen
DE19954421A1 (de) * 1999-11-12 2001-05-31 Lohmann Therapie Syst Lts Filmförmige Zubereitung zur biphasigen Freisetzung pharmakologisch wirksamer oder anderer Substanzen
PL366204A1 (en) * 1999-12-30 2005-01-24 Tap Holdings, Inc. Oral mucosal dosage forms of apomorphine
SE0102036D0 (sv) 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
SE0002934D0 (sv) * 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
DE60138641D1 (de) 2000-10-27 2009-06-18 Baxter Healthcare Sa Herstellung von mikrokügelchen
US6756051B1 (en) 2000-11-15 2004-06-29 Li-Lan H. Chen Bioadhesive, closed-cell foam film, sustained release, delivery devices and methods of making and using same
WO2002062315A1 (en) 2001-02-08 2002-08-15 Pharmacia Corporation Rapid-onset medicament for the treatment of sexual dysfunction
US6976647B2 (en) 2001-06-05 2005-12-20 Elan Pharma International, Limited System and method for milling materials
JP2003006170A (ja) * 2001-06-20 2003-01-10 Hitachi Ltd 複数計算機環境でのプログラム実行方法
US20040028613A1 (en) 2001-06-25 2004-02-12 Nastech Pharmaceutical Company Inc Dopamine agonist formulations for enhanced central nervous system delivery
US20030068356A1 (en) * 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
US8663687B2 (en) 2001-10-12 2014-03-04 Monosol Rx, Llc Film compositions for delivery of actives
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US7910641B2 (en) * 2001-10-12 2011-03-22 Monosol Rx, Llc PH modulated films for delivery of actives
US20080050422A1 (en) 2001-10-12 2008-02-28 Monosolrx, Llc. Method of administering a film product containing a drug
US7425292B2 (en) * 2001-10-12 2008-09-16 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US20110033542A1 (en) * 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US8603514B2 (en) * 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US7666337B2 (en) * 2002-04-11 2010-02-23 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US7357891B2 (en) * 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
FR2832311B1 (fr) * 2001-11-21 2004-04-16 Besins Int Belgique Poudre filmogene, compositions la comprenant, leurs procedes de preparation et leurs utilisations
WO2006031209A1 (en) 2003-05-28 2006-03-23 Monosolrx Llc Polyethylene oxide-based films and drug delivery systems made therefrom
BR0308567A (pt) 2002-03-19 2007-01-09 Michael Holick derivados de glicosìdeo e glicosìdeo de ortoéster de apomorfina, análogos, e seus usos
US8017150B2 (en) * 2002-04-11 2011-09-13 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US6566359B1 (en) * 2002-05-20 2003-05-20 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College 2,4,6-trimethyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid esters as neuroprotective drugs
DE10224612A1 (de) 2002-06-04 2003-12-24 Lohmann Therapie Syst Lts Wirkstoffhaltige filmförmige Zubereitungen mit verbesserter chemischer Stabilität, und Verfahren zu deren Herstellung
GB0221711D0 (en) 2002-09-19 2002-10-30 Ardana Bioscience Ltd Methods
NZ540106A (en) * 2002-11-12 2008-03-28 Teva Pharma Pharmaceutical compositions and dosage forms for buccal and sublingual delivery of tizanidine and methods of administering tizanidine sublingually or bucally
US8999372B2 (en) 2002-11-14 2015-04-07 Cure Pharmaceutical Corporation Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use
AU2003295577A1 (en) 2002-11-14 2004-06-15 Zengen, Inc. Edible film for relief of cough or symptoms associated with pharyngitis
US9561182B2 (en) 2003-08-22 2017-02-07 Cure Pharmaceutical Corporation Edible films for administration of medicaments to animals, methods for their manufacture and methods for their use for the treatment of animals
DK1587504T3 (da) 2003-01-30 2012-07-02 Monosolrx Llc Fremgangsmåde til fremstilling af en tynd film omfattende varmefølsomme aktive stoffer
CA2521624A1 (en) * 2003-04-14 2004-11-11 Shire Laboratories Inc. Pharmaceutical compositions releasing their active agents from a buccal or sublingual location to overcome an absorption window problem
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
CN1460476A (zh) * 2003-06-08 2003-12-10 胡秀爱 可调释药速率的阿扑吗啡舌下滴丸制剂
TW200514579A (en) 2003-07-24 2005-05-01 Smithkline Beecham Corp Orally dissolving films
US9248146B2 (en) * 2003-10-24 2016-02-02 Adhesives Research, Inc. Dissolvable adhesive films for delivery of pharmaceutical or cosmetic agents
ATE500821T1 (de) 2003-12-31 2011-03-15 Cima Labs Inc Brauseformen von opiaten zur oralen anwendung und verfahren zur verabreichung von oxycodon
RU2380092C2 (ru) 2004-01-30 2010-01-27 Кориум Интернэшнл, Инк. Быстро растворяющаяся пленка для доставки активного агента
US7658945B2 (en) * 2004-02-17 2010-02-09 Transcept Pharmaceuticals, Inc. Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
JP4413665B2 (ja) * 2004-03-19 2010-02-10 救急薬品工業株式会社 口腔内粘膜フィルム剤
AU2005232748A1 (en) 2004-04-13 2005-10-27 The Mclean Hospital Corporation R(-)-11-hydroxyaporphine derivatives and uses thereof
DK1799453T3 (da) 2004-09-30 2012-12-17 Monosolrx Llc Flerlagsfilm med ensartet indhold
RU2283650C1 (ru) * 2005-02-24 2006-09-20 Закрытое Акционерное Общество "Канонфарма Продакшн" Твердая лекарственная форма для улучшения мужской эректильной функции
FR2883179B1 (fr) * 2005-03-18 2009-04-17 Ethypharm Sa Comprime enrobe
GB0509317D0 (en) * 2005-05-06 2005-06-15 Clarke Anthony Pharmaceutical formulation of apomorphine
DE102005041860A1 (de) * 2005-09-02 2007-03-08 Schering Ag Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen
CN101316579A (zh) 2005-09-09 2008-12-03 莫诺索尔克斯有限公司 含有抗粘组合物的用于快速溶解剂型的均匀膜
WO2007067494A1 (en) 2005-12-06 2007-06-14 Monosol Rx, Llc Topical film compositions for delivery of actives
AU2006329819A1 (en) * 2005-12-27 2007-07-05 Monosol Rx Llc pH modulated films for delivery of actives
US20070286900A1 (en) * 2006-06-09 2007-12-13 Catherine Herry Low dose tablets of opioid analgesics and preparation process
CN103550136B (zh) 2006-07-21 2016-04-13 生物递送科学国际公司 吸收增强的经粘膜递送装置
MX2009003372A (es) 2006-10-02 2009-09-24 Labtec Gmbh Formas de dosificacion de pelicula no mucoadhesiva.
US20100035886A1 (en) * 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
US7843456B2 (en) * 2007-06-29 2010-11-30 Microsoft Corporation Gradient domain editing of animated meshes
MX2010004265A (es) * 2007-10-19 2010-07-28 Innozen Inc Composicion para administrar un ingrediente activo y metodo para hacer y usar el mismo.
EP2210595A1 (en) * 2009-01-14 2010-07-28 LEK Pharmaceuticals d.d. Active coating of pharmaceutical dosage forms
RU2011149798A (ru) * 2009-05-08 2013-06-20 Дженентек, Инк. Гуманизированные анти-egfl7-антитела и способы их применения
US9044475B2 (en) 2009-06-12 2015-06-02 Cynapsus Therapeutics, Inc. Sublingual apomorphine
ES2791715T3 (es) 2010-12-16 2020-11-05 Sunovion Pharmaceuticals Inc Películas sublinguales
GB201217419D0 (en) 2012-09-28 2012-11-14 Innotesto Bvba Improvements in or relating to oromucosal apomorphine compositions

Also Published As

Publication number Publication date
DK2442650T4 (en) 2025-08-18
PL2442650T5 (pl) 2025-09-08
ES2554626T5 (en) 2025-10-06
JP6141354B2 (ja) 2017-06-07
KR20170027711A (ko) 2017-03-10
PT2442650E (pt) 2015-12-18
US20160089367A1 (en) 2016-03-31
DK2952191T3 (en) 2018-12-10
US9669020B2 (en) 2017-06-06
AU2017200329B2 (en) 2018-11-08
US9669021B2 (en) 2017-06-06
NZ597237A (en) 2014-02-28
IL216923A (en) 2017-08-31
PL2442650T3 (pl) 2016-01-29
EP2442650B1 (en) 2015-08-26
AU2019200308A1 (en) 2019-02-07
JP2018083820A (ja) 2018-05-31
AU2021201259A1 (en) 2021-03-18
EA201270012A1 (ru) 2012-07-30
KR102017009B1 (ko) 2019-09-02
JP2015199743A (ja) 2015-11-12
US9044475B2 (en) 2015-06-02
BR112012000204A2 (pt) 2016-11-01
CN102480958A (zh) 2012-05-30
JP6770126B2 (ja) 2020-10-14
US20160101101A1 (en) 2016-04-14
MX2011013260A (es) 2012-02-28
US9669019B2 (en) 2017-06-06
EP2442650B2 (en) 2025-05-14
JP2016147882A (ja) 2016-08-18
US10420763B2 (en) 2019-09-24
CA2765291A1 (en) 2010-12-16
EP2952191B1 (en) 2018-08-22
KR20190103472A (ko) 2019-09-04
BR112012000204B8 (pt) 2021-05-25
IL253965A0 (en) 2017-10-31
JP6506381B2 (ja) 2019-04-24
HUE028121T2 (en) 2016-11-28
CA2765291C (en) 2016-03-08
CN102480958B (zh) 2015-08-19
US9669018B2 (en) 2017-06-06
EA025054B1 (ru) 2016-11-30
ES2554626T3 (es) 2015-12-22
EP2442650A1 (en) 2012-04-25
AU2010259971A1 (en) 2012-01-19
KR20120042836A (ko) 2012-05-03
US20160081914A1 (en) 2016-03-24
KR20150094648A (ko) 2015-08-19
JP5760295B2 (ja) 2015-08-05
AU2017200329A1 (en) 2017-02-23
US9326981B2 (en) 2016-05-03
JP2019123732A (ja) 2019-07-25
HK1218630A1 (en) 2017-03-03
IL253965B (en) 2022-06-01
KR102086311B1 (ko) 2020-03-06
EP2442650A4 (en) 2012-11-14
EP2952191A1 (en) 2015-12-09
US20200030315A1 (en) 2020-01-30
US20210322403A1 (en) 2021-10-21
ZA201109208B (en) 2013-09-25
BR112012000204B1 (pt) 2020-11-24
JP2012530066A (ja) 2012-11-29
JP2021001209A (ja) 2021-01-07
JP6267254B2 (ja) 2018-01-24
US20160095851A1 (en) 2016-04-07
BR112012000204A8 (pt) 2017-09-19
PT2952191T (pt) 2018-11-30
US20110111011A1 (en) 2011-05-12
US20180289699A1 (en) 2018-10-11
AU2010259971C1 (en) 2017-02-16
KR20180069100A (ko) 2018-06-22
US20150216859A1 (en) 2015-08-06
AU2019200308B2 (en) 2020-11-26
ES2699077T3 (es) 2019-02-07
WO2010144817A1 (en) 2010-12-16
PL2952191T3 (pl) 2019-02-28
DK2442650T3 (en) 2015-12-07
IL216923A0 (en) 2012-02-29
US20160089328A1 (en) 2016-03-31
AU2010259971B2 (en) 2016-10-27
HK1171340A1 (zh) 2013-03-28
EP3434270A1 (en) 2019-01-30

Similar Documents

Publication Publication Date Title
FI2442650T4 (fi) Kielen alle annettava apomorfiini
JP2012512907A5 (fi)
IL195732A (en) Pharmaceutical compounds containing passoterodine, their use and method for their preparation
JP2012092110A5 (fi)
WO2012021629A3 (en) Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
AR079862A1 (es) Composicion de topiramato con sabor enmascarado, un comprimido desintegrable oralmente que comprende la misma y metodo de preparacion
JP2010077141A5 (fi)
IL194871A (en) Compound linking to bir iap site, intermediate compound, process for compound preparation, method for making acceptable pharmaceutical salt, pharmaceutical preparation and use of compound for drug production
FI3782612T3 (fi) Sytidiinianalogien oraalisia formulaatioita ja menetelmiä niiden käyttämiseksi
NZ612686A (en) Sublingual films
IL213323A (en) Causes prevention and / or treatment of an allergic disease containing a low-molecular-weight acid derivative of polysulfate hyaluronic acid, its use or its acceptable medicinal salt, as well as a low-molecular-weight acid derivative of hyaluronic polysulfate and a pharmaceutical preparation containing it
JP2009537554A5 (fi)
HRP20171384T1 (hr) Farmaceutski pripravak
ECSP11011289A (es) Formulaciones galénicas de compuestos orgánicos
JP2010504343A5 (fi)
JP2012502037A5 (fi)
JP2010536889A5 (fi)
NZ595663A (en) Immediate release pharmaceutical compositions comprising oxycodone and naloxone
JP2010535814A5 (fi)
RU2009126767A (ru) Производное 1-фенил-1-тио-d-глюцитола
NZ587897A (en) Drug delivery systems comprising weakly basic drugs and organic acids
WO2007123865A3 (en) Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists
MX2009012523A (es) Composiciones utiles para reducir la nefrotoxicidad y metodos para utilizarlas.
BRPI0817275A2 (pt) Combinação farmacêutica de alisquireno e valsartana
BRPI0507661A (pt) método para aumentar a biodisponibilidade de um composto terapeuticamente ativo, e, uso de um composto ativo